Genmab (GMAB) has released an update.
Genmab A/S, headquartered in Copenhagen, is focused on medical research and the commercialization of related products, with English as its group language. The company has authorized capital increases through the issuance of warrants and convertible debt instruments to employees and has provisions for share capital expansion up to DKK 6,600,000, subject to market value conditions. Genmab’s share structure allows for negotiable instruments with no pre-emption rights for existing shareholders in the case of warrants and convertible debt instruments.
For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.
